Autoantibodies against type I IFNs in patients with critical influenza pneumonia

0301 basic medicine Informe de Investigación Virus de la Influenza A SEVERE COVID-19 Pneumònia DETERMINANTS Autoanticossos Settore MED/03 - GENETICA MEDICA Virus Replication 3C-Dijon Study 03 Salud y bienestar INFECTION Medicine and Health Sciences Prevalence MYASTHENIA-GRAVIS PATIENTS REIPI INF Working Group Yellow Fever Vaccine Autoanticuerpos Influenza A virus Influenza Vaccines Interferon Type I [SDV.IMM]Life Sciences [q-bio]/Immunology BURDEN Constances Cohort INTERFERON Cerba HealthCare Group Anticuerpos SARS-Cov-2 610 IMMUNITY Antibodies Article NEUTRALIZING ANTIBODIES Grip Vacuna contra la Fiebre Amarilla 03 medical and health sciences 616 Neumonía Influenza, Human [SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] Gripe Humana Type I interferons Interferón Tipo I Humans COVID Human Genetic Effort 320505 Enfermedades infecciosas Autoantibodies Células A549 [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics Etablissement Français du Sang Study Group COVID-19 Pneumonia ALLELES Lyon Antigrippe Working Group Influenza ALPHA A549 Cells 03 Good Health and Well-being 32 Ciencias médicas
DOI: 10.1084/jem.20220514 Publication Date: 2022-09-16T14:15:36Z
AUTHORS (244)
ABSTRACT
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10−5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (88)
CITATIONS (75)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....